Rossi Maura, Laginestra Maria Antonella, Gazzola Anna, Sapienza Maria Rosaria, Pileri Stefano A, Piccaluga Pier Paolo
Molecular Pathology Laboratory, Haematopathology Unit, Department of Haematology and Oncology "L. and A. Seràgnoli", S. Orsola-Malpighi Hospital, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy.
Adv Hematol. 2012;2012:464680. doi: 10.1155/2012/464680. Epub 2011 Nov 24.
In the last years, several studies of molecular profiling of aggressive lymphomas were performed. In particular, it was shown that DLBCL can be distinguished in two different entities according to GEP. Specifically, ABC and GCB subtypes were characterized by having different pathogenetic and clinical features. In addition, it was demonstrated that DLBCLs are distinct from BL. Indeed, the latter is a unique molecular entity. However, relevant pathological differences emerged among the clinical subtypes. More recently, microRNA profiling provided further information concerning BL-DLBCL distinction as well as for their subclassification. In this paper, the authors based on their own experience and the most updated literature review, the main concept on molecular profiling of aggressive lymphomas.
在过去几年中，对侵袭性淋巴瘤进行了多项分子谱分析研究。特别是，根据基因表达谱（GEP）显示弥漫性大B细胞淋巴瘤（DLBCL）可分为两种不同的实体。具体而言，ABC和GCB亚型具有不同的发病机制和临床特征。此外，已证明DLBCL与伯基特淋巴瘤（BL）不同。事实上，后者是一个独特的分子实体。然而，临床亚型之间出现了相关的病理差异。最近，微小RNA谱分析为BL-DLBCL的区分及其亚分类提供了更多信息。在本文中，作者基于自身经验和最新的文献综述，阐述了侵袭性淋巴瘤分子谱分析的主要概念。
